CRISPR Therapeutics Stock Income Statements

CRISPR Therapeutics Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Gross Profit

Operating Profit

Net Income

CRISPR Therapeutics Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2023-12-31	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31
revenue	200,000,000	70,000,000	100,000,000	6,000	94,000	158,000	178,000	12,348,000	329,000	900,202,000	202,000	194,000	148,000	44,000	157,000	77,016,000	211,928,000	318,000	328,000	115,000	563,000	1,088,000	1,358,000	32,325,000	2,387,000	3,582,000	2,703,000	2,344,000	1,549,000	795,000	476,000	247,000
cost of revenue	20,000,000	44,636,000	42,192,000	6,823,000	38,859,000	33,922,000	30,646,000	134,919,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
gross profit	180,000,000	25,364,000	57,808,000	-6,817,000	-38,765,000	-33,764,000	-30,468,000	-122,571,000	329,000	900,202,000	202,000	194,000	148,000	44,000	157,000	77,016,000	211,928,000	318,000	328,000	115,000	563,000	1,088,000	1,358,000	32,325,000	2,387,000	3,582,000	2,703,000	2,344,000	1,549,000	795,000	476,000	247,000
operating expenses
research and development	95,144,000	101,555,000	99,935,000	103,555,000	116,622,000	123,223,000	118,245,000	134,470,000	105,321,000	108,277,000	90,565,000	82,365,000	71,008,000	59,380,000	54,193,000	48,762,000	57,246,000	39,533,000	33,822,000	28,801,000	39,820,000	25,633,000	19,519,000	20,030,000	17,845,000	17,120,000	14,805,000	15,572,000	12,052,000	8,602,000	6,012,000	6,174,000
sales, general and administrative
total operating expenses	110,417,000	120,587,000	122,295,000	124,724,000	143,623,000	149,496,000	145,504,000	158,046,000	129,178,000	137,584,000	114,745,000	107,955,000	92,547,000	80,733,000	73,743,000	66,033,000	72,765,000	55,301,000	48,751,000	45,343,000	49,995,000	38,374,000	28,355,000	31,353,000	25,957,000	24,888,000	23,447,000	27,654,000	16,159,000	17,353,000	12,128,000	12,413,000
operating income	69,583,000	-95,223,000	-64,487,000	-131,541,000	-182,388,000	-183,260,000	-175,972,000	-145,698,000	-128,849,000	762,618,000	-114,543,000	-107,761,000	-92,399,000	-80,689,000	-73,586,000	10,983,000	139,163,000	-54,983,000	-48,423,000	-45,228,000	-49,432,000	-37,286,000	-26,997,000	972,000	-23,570,000	-21,306,000	-20,744,000	-25,310,000	-14,610,000	-16,558,000	-11,652,000	-12,166,000
net income	89,347,000	-77,740,000	-53,065,000	-110,575,000	-174,549,000	-185,834,000	-179,217,000	-141,248,000	-127,153,000	759,225,000	-113,163,000	-107,039,000	-92,439,000	-79,656,000	-69,731,000	30,542,000	138,423,000	-53,699,000	-48,408,000	-47,590,000	-50,711,000	-38,380,000	-28,300,000	141,000	-24,707,000	-22,315,000	-21,475,000	17,098,000	-14,694,000	-17,164,000	-8,442,000	-12,286,000

We provide you with 20 years income statements for CRISPR Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CRISPR Therapeutics stock. Explore the full financial landscape of CRISPR Therapeutics stock with our expertly curated income statements.

The information provided in this report about CRISPR Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.